Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
BGC20-0166
- Development stage
- Discontinued
- Lead developer
- BTG International
- Modality
- Small Molecules
- Administration
- Oral
01
Overview
**BGC20-0166** was a BTG-developed, proprietary oral combination of **fluoxetine** and **ondansetron** investigated for obstructive sleep apnea. Fluoxetine inhibits serotonin reuptake through the serotonin transporter, while ondansetron antagonizes the 5-hydroxytryptamine receptor 3. The serotonergic combination was intended to improve sleep-related breathing by supporting upper-airway dilator-muscle tone and respiratory drive across non-rapid-eye-movement and rapid-eye-movement sleep. BTG reported statistically significant apnea-hypopnea-index reductions with the high-dose combination in a proof-of-concept study, and subsequently worked with Collegium Pharmaceutical on a proprietary formulation for a planned US IND program. ([businesswire.com](https://www.businesswire.com/news/home/20080410005406/en/BTG-Reports-Positive-Results-Study-Investigating-BGC20-0166))
- Other names
- fluoxetine + ondansetronOND+FLondansetron + fluoxetine
02
Targets
SERT (Sodium-dependent serotonin transporter)HTR3A (5-hydroxytryptamine receptor 3A)
Beyond the preview
Go deeper on BGC20-0166.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on BGC20-0166.